Masoprocol
Chemical compound
- L01XX10 (WHO)
- 4-[(2R,3S)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
- 27686-84-6 Y
- 71398
- 4265
- DB00179 Y
- 64490 Y
- 7BO8G1BYQU
- CHEBI:73468 N
- ChEMBL313972 N
- DTXSID5045178
- Interactive image
- Oc1ccc(cc1O)C[C@H](C)[C@H](C)Cc2ccc(O)c(O)c2
InChI
- InChI=1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3/t11-,12+ Y
- Key:HCZKYJDFEPMADG-TXEJJXNPSA-N Y
Masoprocol is an antineoplastic drug used to treat skin growths caused by sun exposure. It is the meso form of nordihydroguaiaretic acid that is taken by mouth. The substance is being studied in the treatment of prostate cancer.
Masoprocol is also called NDGA, and Actinex.
Mechanism
Nordihydroguaiaretic acid is an antioxidant, and it may block certain enzymes needed for tumor growth.
It is a lipoxygenase inhibitor.[1]
References
- ^ Gowri MS, Azhar RK, Kraemer FB, Reaven GM, Azhar S (September 2000). "Masoprocol decreases rat lipolytic activity by decreasing the phosphorylation of HSL". American Journal of Physiology. Endocrinology and Metabolism. 279 (3): E593-600. doi:10.1152/ajpendo.2000.279.3.E593. PMID 10950827.
External links
- MedlinePlus Drug Information
- Actinex entry in the public domain NCI Cancer Dictionary
- v
- t
- e
(M phase)
Block microtubule assembly | |
---|---|
Block microtubule disassembly |
inhibitor
DNA precursors/ antimetabolites (S phase) |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Topoisomerase inhibitors (S phase) |
| ||||||||
Crosslinking of DNA (CCNS) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e